Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27260850 | 0.92 | PRMT1 (0.47) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL19645170 | 0.92 | ADRA1A (0.53) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL26905191 | 0.92 | GLP1R (0.53) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL27288091 | 0.92 | GLP1R (0.50) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL22648076 | 0.92 | GLP1R (0.53) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL27328538 | 0.91 | ADRA1A (0.47) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL26297889 | 0.91 | GLP1R (0.57) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL27661517 | 0.90 | PRMT1 (0.52) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL27331406 | 0.90 | PRMT1 (0.52) | PRMT1ADRA1AITGB3ITGA2BGLP1R | |
| SCHEMBL26904870 | 0.89 | PRMT1 (0.45) | PRMT1ADRA1AITGB3ITGA2BGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186603-B2 | Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses | VICTORIA LINK LIMITED (NZ) | 2021-11-30 | — | — | US | disclosed |
| US-20200131217-A1 | HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMECEUTICAL USES | VICTORIA LINK LIMITED (NZ) | 2020-04-30 | — | — | US | disclosed |
| US-9879041-B2 | Saccharide dendritic cluster compounds as inhibitors of BACE-1 | VICTORIA LINK LIMITED (NZ) | 2018-01-30 | — | — | US | disclosed |
| US-9828341-B2 | Dendritic core compounds | VICTORIA LINK LIMITED (NZ) | 2017-11-28 | — | — | US | disclosed |
| US-9828341-B2 | Dendritic core compounds | VICTORIA LINK LIMITED (NZ) | 2017-11-28 | — | — | US | disclosed |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2015-10-15 | — | — | US | disclosed |
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2015-10-15 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | FLOT1, DBN1, DCTN3 | PRMT1 3059/4885ADRA1A 1623/4885ITGB3 266/4885 |
| US-20200131217-A1 | HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMECEUTICAL USES | GBA1, UGCG, GBA2 | PRMT1 4812/4885ADRA1A 4413/4885ITGB3 2872/4885 |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | PRMT1 2836/4885ADRA1A 2443/4885ITGB3 1365/4885 |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | PRMT1 2836/4885ADRA1A 2443/4885ITGB3 1365/4885 |
| US-11186603-B2 | Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses | GBA1, UGCG, GBA2 | PRMT1 4812/4885ADRA1A 4413/4885ITGB3 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.